RISE Adult Medication Study



Status:Active, not recruiting
Conditions:Endocrine, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:20 - 65
Updated:9/2/2018
Start Date:April 2013
End Date:August 2019

Use our guide to learn which trials are right for you!

Restoring Insulin Secretion Adult Medication Study

The RISE Adult Medication Study is a 4-arm, 3-center, clinical trial of adults with
prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose
lowering will lead to recovery of beta-cell function that will be sustained after withdrawal
of treatment. Adult participants (ages 20-65) will be randomized to one of the following
treatment regimens: (1) blinded placebo, (2) blinded metformin alone, (3) early intensive
insulin treatment with basal insulin glargine followed by open-label metformin, (4) the
glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide plus open-label metformin.

The primary clinical question RISE will address is: Are improvements in ß-cell function
following 12 months of active treatment maintained for 3 months following the withdrawal of
therapy? Secondary outcomes will assess durability of glucose tolerance following withdrawal
of therapy, and whether biomarkers obtained in the fasting state predict parameters of ß-cell
function, insulin sensitivity and glucose tolerance and the response to an intervention.


Inclusion Criteria:

1. Fasting plasma glucose 95-125 mg/dl plus 2-hour glucose ≥140 mg/dl on 75 gm OGTT plus
HbA1c ≤7.0%. There is no upper limit for the 2-hour glucose on OGTT.

2. Age 20-65 years

3. Body mass index (BMI) ≥25 kg/m2 but ≤50 kg/m2

4. Self-reported diabetes <1 year in duration

5. Drug naïve (no prior to oral glucose lowering agent(s), insulin or other injectable
glucose lowering agents)

Exclusion Criteria:

1. Underlying disease likely to limit life span and/or increase risk of intervention or
an underlying condition that is likely to limit ability to participate in outcomes
assessment

2. An underlying disease that affects glucose metabolism other than type 2 diabetes

3. Taking medications that affect glucose metabolism, or has an underlying condition that
is likely to require such medications

4. Active infections

5. Renal disease (serum creatinine >1.4 mg/dl for men; >1.3 mg/dl for women) or serum
potassium abnormality (<3.4 or >5.5 mmol/l)

6. Anemia (hemoglobin <11 g/dl in women, <12 g/dl in men) or known coagulopathy

7. Cardiovascular disease, including uncontrolled hypertension. Participants must be able
to safely tolerate administration of intravenous fluids required during clamp studies.

8. History of conditions that may be precipitated or exacerbated by a study drug:

1. Pancreatitis

2. Serum alanine transaminase (ALT) more than 3 times the upper limit of normal

3. Excessive alcohol intake

4. Suboptimally treated thyroid disease

5. Medullary carcinoma of the thyroid or MEN-2 (in participant or a family history)

6. Hypertriglyceridemia (>400 mg/dl despite treatment)

9. Conditions or behaviors likely to affect the conduct of the RISE Study

1. Unable or unwilling to give informed consent

2. Unable to adequately communicate with clinic staff

3. Another household member is a participant or staff member in RISE

4. Current, recent or anticipated participation in another intervention research
project that would interfere with any of the interventions/outcomes in RISE

5. Weight loss of >5% in past three months for any reason other than post-partum
weight loss. Participants taking weight loss drugs or using preparations taken
for intended weight loss are excluded.

6. Likely to move away from participating clinics in next two years

7. Women of childbearing potential who are unwilling to use adequate contraception

8. Current (or anticipated) pregnancy and lactation.

9. Major psychiatric disorder that, in the opinion of clinic staff, would impede the
conduct of RISE

10. Additional conditions may serve as criteria for exclusion at the discretion of the
local site.
We found this trial at
4
sites
425 University Blvd.
Indianapolis, Indiana 46202
(317) 274-4591
Principal Investigator: Kieren Mather, MD
Phone: 317-274-7679
Indiana University INDIANA UNIVERSITY is a major multi-campus public research institution, grounded in the liberal...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Principal Investigator: David Ehrmann, MD
Phone: 773-702-4295
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1660 South Columbian Way
Seattle, Washington 98108
(206) 762-1010
Principal Investigator: Steven Kahn, MB, ChB
Phone: 206-764-2788
VA Puget Sound Health Care System With a reputation for excellence, innovation and extraordinary care...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Chicago, Illinois 60612
?
mi
from
Chicago, IL
Click here to add this to my saved trials